These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

86 related items for PubMed ID: 3030197

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. [Phase II study of recombinant human interferon gamma (S-6810) in renal cell carcinoma. Urological Cooperative Study Group of Recombinant Human Interferon Gamma (S-6810)].
    Machida T, Koiso K, Takaku F, Ogawa M.
    Gan To Kagaku Ryoho; 1987 Feb; 14(2):440-5. PubMed ID: 3101607
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. A phase I trial of recombinant human gamma interferon (IFN-gamma 4A) in patients with advanced malignancy.
    Perez R, Lipton A, Harvey HA, Simmonds MA, Romano PJ, Imboden SL, Giudice G, Downing MR, Alton NK.
    J Biol Response Mod; 1988 Jun; 7(3):309-17. PubMed ID: 3134513
    [Abstract] [Full Text] [Related]

  • 8. Recombinant interferon alpha and gamma in combination as treatment for metastatic renal cell carcinoma.
    Quesada JR, Evans L, Saks SR, Gutterman JU.
    J Biol Response Mod; 1988 Jun; 7(3):234-9. PubMed ID: 3134511
    [Abstract] [Full Text] [Related]

  • 9. Phase I/II trial of human recombinant interferon gamma in renal cell carcinoma.
    Rinehart JJ, Malspeis L, Young D, Neidhart JA.
    J Biol Response Mod; 1986 Aug; 5(4):300-8. PubMed ID: 3090208
    [Abstract] [Full Text] [Related]

  • 10. [Phase II study of recombinant leukocyte A interferon (Ro 22-8181) in skin malignant tumors].
    Gan To Kagaku Ryoho; 1985 Apr; 12(4):936-42. PubMed ID: 2985007
    [Abstract] [Full Text] [Related]

  • 11. NTP Toxicology and Carcinogenesis Studies of Coumarin (CAS No. 91-64-5) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
    National Toxicology Program .
    Natl Toxicol Program Tech Rep Ser; 1993 Sep; 422():1-340. PubMed ID: 12616289
    [Abstract] [Full Text] [Related]

  • 12. Feasibility and pharmacokinetics of continuous subcutaneous infusion of low-dose interferon-gamma: a pilot study.
    Satake I, Tari K, Nakagomi K, Ozawa K.
    Jpn J Clin Oncol; 1993 Dec; 23(6):356-62. PubMed ID: 8283789
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Phase I study of i.v. administered recombinant gamma interferon in cancer patients.
    Kurzrock R, Quesada JR, Rosenblum MG, Sherwin SA, Gutterman JU.
    Cancer Treat Rep; 1986 Dec; 70(12):1357-64. PubMed ID: 3098417
    [Abstract] [Full Text] [Related]

  • 15. NTP Toxicology and Carcinogenesis Studies of 1-Amino-2,4-Dibromoanthraquinone (CAS No. 81-49-2) in F344/N Rats and B6C3F1 Mice (Feed Studies).
    National Toxicology Program .
    Natl Toxicol Program Tech Rep Ser; 1996 Aug; 383():1-370. PubMed ID: 12692653
    [Abstract] [Full Text] [Related]

  • 16. [Interferon (IFN) therapy (recombinant IFN-alpha-2C or recombinant IFN-gamma) in metastasized hypernephroma].
    Kuzmits R, Scheithauer W, Ludwig H, Flener R.
    Acta Med Austriaca; 1985 Aug; 12(5):129-34. PubMed ID: 3938590
    [Abstract] [Full Text] [Related]

  • 17. [Effects of interferon on various malignancies].
    Taguchi T.
    Gan To Kagaku Ryoho; 1984 Feb; 11(2):194-204. PubMed ID: 6696457
    [Abstract] [Full Text] [Related]

  • 18. Phase I trial of twice-weekly intravenous interleukin 12 in patients with metastatic renal cell cancer or malignant melanoma: ability to maintain IFN-gamma induction is associated with clinical response.
    Gollob JA, Mier JW, Veenstra K, McDermott DF, Clancy D, Clancy M, Atkins MB.
    Clin Cancer Res; 2000 May; 6(5):1678-92. PubMed ID: 10815886
    [Abstract] [Full Text] [Related]

  • 19. Phase I trial of recombinant macrophage colony-stimulating factor and recombinant gamma-interferon: toxicity, monocytosis, and clinical effects.
    Weiner LM, Li W, Holmes M, Catalano RB, Dovnarsky M, Padavic K, Alpaugh RK.
    Cancer Res; 1994 Aug 01; 54(15):4084-90. PubMed ID: 8033141
    [Abstract] [Full Text] [Related]

  • 20. Immunomodulation by recombinant interferon-alpha 2 in a phase I trial in patients with lymphoproliferative malignancies.
    Ozer H, Gavigan M, O'Malley J, Thompson D, Dadey B, Nussbaum-Blumenson A, Snider C, Rudnick S, Ferraresi R, Norred S.
    J Biol Response Mod; 1983 Aug 01; 2(6):499-515. PubMed ID: 6607323
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.